Miruvor
Sign up
The short answer

What studies of zinc found

29papers on zinc
1 (few people)person in 1 study testing zinc alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 3 of 4 findings are C.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Zinc might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 29 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Zinc · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Anxiety1 study · 1 (few people) person took zinc Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over a three-month follow-up period · 75 mg twice daily (few people)

Anxiety improved.

The evidence is very uncertain about the effect of zinc on anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Executive Dysfunction After COVID-19 in an Older Adult With Type 1 Diabetes: A Case of Insulin Pump Discontinuation. (2025)

    People in the study
    1 in the study
    Dose
    75 mg twice daily
    Outcome
    adherence, confidence, and treatment-related anxiety
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Smell and taste loss1 study · 1 (few people) person took zinc Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over a three-month follow-up period · 75 mg twice daily (few people)

Smell and taste loss improved.

The evidence is very uncertain about the effect of zinc on smell and taste loss in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Executive Dysfunction After COVID-19 in an Older Adult With Type 1 Diabetes: A Case of Insulin Pump Discontinuation. (2025)

    People in the study
    1 in the study
    Dose
    75 mg twice daily
    Outcome
    taste perception and appetite
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 1 (few people) person took zinc Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).

Studies with no comparison group1 in the study · over a three-month follow-up period · 75 mg twice daily (few people)

No clear change in breathlessness.

The evidence is very uncertain about the effect of zinc on breathlessness in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
See the 1 study
  1. Executive Dysfunction After COVID-19 in an Older Adult With Type 1 Diabetes: A Case of Insulin Pump Discontinuation. (2025)

    People in the study
    1 in the study
    Dose
    75 mg twice daily
    Outcome
    COVID-19 course remained clinically mild, without respiratory deterioration
    Effect
    no clear difference
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms1 study · 1 (few people) person took zinc Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over a three-month follow-up period · 75 mg twice daily (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of zinc on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance

Combination: Chinese, Japanese and Korean herbal medicine + proton pump inhibitor + Epipharyngeal abrasive therapy (EAT) + Acupuncture + Moxibustion + Zinc + Antihistamines (unspecified) + Mirtazapine (Remeron) + Sleeping pills (unspecified) + Nasal saline rinses and sprays (neti pot)128 in the study · 114 with outcome data

Factors involved in the improvement of prolonged symptoms in patients with COVID-19 treated with Japanese traditional (Kampo) medicine: A single-center, prospective, observational study. (2026): the end of visit milestone, better (not tested).

Shown, not counted: zinc was given together with other treatments.

See the 1 study
  1. Executive Dysfunction After COVID-19 in an Older Adult With Type 1 Diabetes: A Case of Insulin Pump Discontinuation. (2025)

    People in the study
    1 in the study
    Dose
    75 mg twice daily
    Outcome
    clinical stabilization
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Studies of combinations

Outcomes that only studies of zinc given together with other treatments looked at. Shown, not graded: they can’t tell what zinc did alone.

Overall symptoms ME/CFS

Combination: Glutamine + NAC (N-acetylcysteine) + Zinc + Leaky gut protocol and supplements + L-carnitine + CoQ10 / ubiquinol + Taurine + Alpha-lipoic acid (ALA, R-ALA) + Turmeric / curcumin + Baicalein and quercetin41 in the study

Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. (2008): Fibromyalgia and Chronic Fatigue Syndrome Rating Scale (FF scale), better (not tested).

Shown, not counted: zinc was given together with other treatments.

Daily functioning Long COVID

Combination: Chinese, Japanese and Korean herbal medicine + proton pump inhibitor + Epipharyngeal abrasive therapy (EAT) + Acupuncture + Moxibustion + Zinc + Antihistamines (unspecified) + Mirtazapine (Remeron) + Sleeping pills (unspecified) + Nasal saline rinses and sprays (neti pot)128 in the study · 114 with outcome data

Factors involved in the improvement of prolonged symptoms in patients with COVID-19 treated with Japanese traditional (Kampo) medicine: A single-center, prospective, observational study. (2026): PS ≤ 2, better (not tested).

Shown, not counted: zinc was given together with other treatments.

Fatigue ME/CFS

Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed

Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): perception of physical fatigue (physical functioning domain), better.

Shown, not counted: zinc was given together with other treatments.

Cognition (brain fog) ME/CFS

Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed

Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): cognitive domain, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Daily functioning ME/CFS

Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed

Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): psychological domain, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Pain ME/CFS

Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed

Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): bodily pain, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Quality of life ME/CFS

Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed

Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): mental component summary, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Low mood or anxiety ME/CFS

Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed

Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): emotional role functioning, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Sleep ME/CFS

Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed

Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): any component of the self-administered scale, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Fatigue Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): General fatigue, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Daily functioning Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Time to exhaustion (sec), no clear difference.

Shown, not counted: zinc was given together with other treatments.

Smell and taste loss Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Anosmia, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Pain Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Lung pain, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Breathlessness Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Breathing difficulties, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Cognition (brain fog) Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Difficulties concentrating, no clear difference.

Shown, not counted: zinc was given together with other treatments.

Post-exertional malaise Both together

Combination: Probiotics and fermented foods + Prebiotics + Zinc26 randomised

The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. (2024): Post-exercise malaise, better.

Shown, not counted: zinc was given together with other treatments.

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    10 to 50 mg at the start in most studies

  2. 2Top dose

    Most often 10 mg (2 of 7 studies)

All papers

  1. Effect of drug therapies on self-reported chemosensory outcomes after COVID-19.2024 · compared with another group · 714 in the study
    Summary

    This cross-sectional study interviewed 714 people with self-reported post-COVID-19 taste and/or smell disorders, recruited through advertisements on social networks, a median of 81 days (interquartile range 60–104) after COVID-19 symptom onset. Of these, 437 used at least one medication for COVID-19 and 277 used none; treatment duration was not reported. The main measure was self-reported total recovery of smell and taste, with severity also rated 0–10. Total recovery was reported by 249 (34.9%). The recovery rates of the treated and nontreated groups did not differ significantly. In adjusted models, oral zinc was associated with lower odds of return to normal olfaction or taste capacity (odds ratio 0.24; 95% CI 0.1–0.5; p < 0.001), and nitazoxanide had an odds ratio of 3.30 (95% CI 1.35–8.20; p = 0.009), although the text states findings for nitazoxanide, systemic corticosteroids, and azithromycin did not reach statistical significance after Bonferroni correction. Adverse events were reported in 55 out of 483 (11.4%) medication users; side-effect percentages were 22.4% for chloroquine or hydroxychloroquine, 14.3% for azithromycin, and 13.9% for oral zinc. Withdrawals related to harms were not reported. The paper also reports 437 medication users in the results and 483 in the adverse-event section.

  2. Symptom Profile of Patients With Post-COVID-19 Conditions and Influencing Factors for Recovery.2023 · compared with another group · 120 in the study · 108 with outcome data
    Summary

    This single-institutional descriptive epidemic study examined factors influencing improvement of post-COVID-19 conditions in 120 symptomatic outpatients (44 males and 76 females) who visited an outpatient department. The retrospective analysis followed symptoms only in patients whose course could be followed for 12 weeks; 108 were followed up after 12 weeks. For hypozincemia, patients received 50 mg zinc acetate hydrate tablets twice a day and continued until healed; 53 cases with Zn levels below 80 mg/dL were users of prescribed zinc acetate hydrate. Outcomes were improvement of symptoms at 4, 8, and 12 weeks after onset, comparing the zinc acetate hydrate group with an untreated group. Fatigue was improved in all cases treated with zinc acetate hydrate 8 weeks later, with a significant difference from the untreated group (P = 0.030); at 12 weeks the trend was similar but not significant (P = 0.060). Hair loss showed significant improvements at 4, 8, and 12 weeks (P = 0.002, P = 0.002, and P = 0.006). No significant difference was found for taste disorder or olfactory disorder with zinc acetate hydrate. In multivariate analysis at 4 weeks, use of zinc acetate hydrate had an odds ratio of 48.03 (95% CI 2.74 - 840.50; P = 0.008) for hair loss improvement. Harms and side effects were not reported.

  3. Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study.2022 · compared with another group · 923 in the study
    Summary

    This longitudinal survey followed recovered COVID-19 patients from Indonesia who were diagnosed by PCR/antigen testing and had recovered less than 30 days after onset. A total of 923 participants’ data were extracted; 168 people were fully vaccinated more than 14 days after a second dose, 41 had received one dose, and 713 were unvaccinated at diagnosis. Participants reported post-COVID symptoms every 30 days for a total of 90 days after onset or diagnosis. The study compared fully vaccinated participants with those who had one dose or were unvaccinated, and compared timing of Favipiravir, vitamin C, vitamin D, and zinc with early initiation or no treatment. For any post-COVID symptoms in 90 days, there was no difference between fully vaccinated and incomplete or unvaccinated individuals after adjustment (aOR 0.74, 95% CI 0.51–1.08, p = 0.118). Complete vaccination was associated with lower odds of chronic cough (aOR 0.527, 95% CI 0.286–0.971, p = 0.040), chronic headache (aOR 0.317, 95% CI 0.163–0.616, p = 0.001), and chronic arthritis (aOR 0.285, 95% CI 0.116–0.703, p = 0.006). Not taking Favipiravir was associated with lower odds of arthritis than taking it within 24 hours (aOR 0.503, 95% CI 0.287–0.882, p = 0.017). Vitamin C later than 72 hours was associated with lower odds of the overall event than vitamin C within 24 hours (aOR 0.63, 95% CI 0.39–0.99, p = 0.048). The combination of micronutrient supplementations and Favipiravir gave no significant effect in seven outcomes. Harms were not reported for this cohort.

  4. Integrating the patient's voice into the research agenda for treatment of chemosensory disorders.2024 · no comparison group · 6,100 in the study · 5,815 started · 4,877 with outcome data
    Summary

    This online questionnaire study asked US residents about treatments for chemosensory impairment, mostly associated with long COVID but with other etiologies included. A total of 6,100 participants provided electronic informed consent and completed the survey; 5,815 indicated they resided in the United States, and 4,877 patients were included in the analysis. Participants rated treatments they had been prescribed—nasal steroids, oral steroids, nasal rinse, smell training, theophylline, alpha lipoic acid, omega-3, and platelet-rich plasma—as extremely effective, very effective, moderately effective, slightly effective, or not effective at all. The study did not administer treatments or include a comparison group; patients reported different olfactory training regimens and complied for different durations. The most consistent predictor of efficacy was age: the majority of those 40 to 60 and 60+ rated nasal and oral steroids, zinc, nasal rinse, and smell training only slightly effective or not effective at all. Nasal steroids were rated slightly effective or not effective at all by 91% of those 40 to 60 years and 93% of those 60+ years. Smell training was rated slightly effective or not effective at all by 89% of those 60+ and 91% of those 40 to 60 years; 790 individuals reported using smell training. Differences were not significant for theophylline or PRP but samples were small. Harms were not reported.

  5. Synbiotic Supplementation Improves Quality of Life and Inmunoneuroendocrine Response in Patients with Fibromyalgia: Influence of Codiagnosis with Chronic Fatigue Syndrome.2023 · no comparison group · 15 in the study
    Summary

    This pilot study enrolled 15 women diagnosed with fibromyalgia (FM), 7 with and 8 without a previous diagnosis of chronic fatigue syndrome (CFS), from an FM association in Badajoz, Extremadura (Spain). Participants took the synbiotic Gasteel Plus® as one stick a day, preferably in the morning and mixed in water, for 30 days; each was evaluated at baseline and after the intervention, which lasted one month. The study had no comparison group. Outcomes included body composition by bioimpedance, activity and sleep by accelerometry, validated questionnaires, and IL-8, IL-10, cortisol and DHEA. The paper reports statistically significant improvements in perceived depression, stress, anxiety, fatigue and fibromyalgia impact on daily activity in the total group (p < 0.05); depression and stress improved only in FM patients without CFS, while anxiety, fatigue and FM impact improved only in the FM + CFS group. No significant changes were reported in weight, body fat mass percentage, bone mass, total body water percentage or muscle mass. The visceral fat index decreased statistically significant in FM patients without a codiagnosis of CFS, but without a physiological relevance. Pain, sleep quality and gastrointestinal health improved without statistical significance. The authors state there were no detrimental changes in body composition or sleep parameters.

  6. The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID.2022 · no comparison group · 51 in the study
    Summary

    This one-arm, open-labeled study at a single site enrolled 51 eligible patients from 18 states with long-haul COVID, recruited from the local patient population and through social media advertising. Participants took a nutraceutical formulation as one serving twice a day with food for 4 weeks, with no comparison group. They rated the severity of 12 symptoms and their general wellbeing at baseline, 2- and 4-week time points. The authors report that on average all symptoms were significantly milder after 2 weeks, with further improvement after 4 weeks, and that the decrease in severity of all symptoms was statistically significant at both the 2- and 4-week time points. Each symptom was reported as significantly attenuated in 72 to 84% of participants, 46 out of 51 participants reported more symptoms that improved than worsened, 59% reported a noticeable improvement in general wellbeing, and the general profile improved for 88% of participants. Minor adverse events included three patients with vertigo and one patient each with increased anxiety, a gout attack, increased joint pain and reinfection with COVID; among the remaining five participants, one reported feeling a worsening in general wellbeing. The authors state the study had no placebo.

  7. Executive Dysfunction After COVID-19 in an Older Adult With Type 1 Diabetes: A Case of Insulin Pump Discontinuation.2025 · case report · 1 in the study
    Summary

    This case report described one 73-year-old woman with a 28-year history of T1DM who developed fatigue, dysgeusia, appetite loss and recurrent diabetic ketoacidosis after COVID-19. She received oral polaprezinc 75 mg twice daily, later switched to zinc acetate hydrate 50 mg elemental zinc/day; oral molnupiravir 800 mg twice daily for five days; esomeprazole 20 mg daily; and, at admission for DKA, continuous intravenous insulin infusion and isotonic saline. There was no comparison group; outcomes were within-patient changes. Zinc supplementation was associated with gradual improvement in taste perception and appetite, and serum zinc rose from 63 μg/dL to 168 μg/dL, above the reference range 80-130 μg/dL. After switching from CSII to MDI, glycemic control stabilized, with no further DKA, improved treatment adherence, enhanced confidence and reduced treatment-related anxiety; by the end of the observation period she had regained her prior level of independence and expressed satisfaction with the MDI regimen. Harms included two hospitalizations for DKA and one additional hospitalization for post-COVID-19 anorexia and nutritional decline over a three-month follow-up period; CSII was transitioned to MDI due to persistent pump-related errors and reduced confidence. The authors state that direct pump log review was not possible and formal executive function tests were not conducted.

  8. Clinical characteristics of endocrine disturbances in post-COVID-19 condition, case report with review of literature2024 · case report · 5 in the study
    Summary

    This case report with review of literature reports on five patients with confirmed SARS-CoV-2 infection for over three months who were hospitalised in the Endocrinology Department of the Second Affiliated Hospital of Ningxia Medical University from June 12, 2023 to July 7, 2023 with post-COVID-19 condition (PCC). There was no comparison group. Treatments included ACTH injection, recombinant human GH injection, oral synthetic glucocorticoids (prednisone acetate or methylprednisolone), hydrocortisone, finerenone, and nirmatrelvir/ritonavir in one patient; duration and follow-up varied by patient, with follow-up at one week, one month, and three months. Dynamic endocrine testing included ITT, arginine stimulation test, rapid ACTH stimulation test, and supine–standing test; pituitary MRI and adrenal CT were performed in one patient. All five patients had hypothalamic syndrome with secondary adrenal insufficiency, growth hormone deficiency, and secondary hyperaldosteronism. The abstract states remarkable improvement was observed within one week for all patients; the Discussion states all patients showed remarkable improvement after just one to four weeks of multi-hormone combination therapy. One patient self-discontinued ACTH and rhGH one month later and reported regaining the ability to perform daily work. The authors write that the origin of these disturbances remains unclear and that discerning whether abnormalities in ACTH, cortisol, and GH secretion are attributable to hypothalamic damage is challenging in clinical practice.

  9. Long COVID-associated Brain Fog and Therapeutic Intervention Using Repetitive Transcranial Magnetic Stimulation(rTMS)2022 · case report · 1 in the study
    Summary

    This is a single case report (症例提示) of one patient with long COVID-associated brain fog seen at the author's post-COVID outpatient clinic in Japan. The patient was given high-frequency rTMS at 10 Hz, 1,200 pulses to each target site (bilateral occipital lobes and the right dlPFC), at an intensity of 90% of the minimum motor threshold required for upper-limb motor area stimulation, once weekly for 10 consecutive sessions. There was no comparison group and no randomisation. Brain fog improved markedly immediately after the first rTMS session. At the end of the 10th session, memory-related failures slightly remained while visuospatial failures were absent; the patient could read without difficulty and join conversations without stagnation, the planned demotion was withdrawn and he returned to full work. At follow-up 1 month after the end of rTMS there was no re-exacerbation of symptoms; fatigue was not entirely absent but recovered with one night's sleep, and clock drawing was correct. No adverse events occurred during the rTMS period. The authors state that many questions remain about the specific method — frequency, stimulation intensity, number of sessions and especially the stimulation site — and that their method is not considered optimal.

  10. Normalization of the increased translocation of endotoxin from gram negative enterobacteria (leaky gut) is accompanied by a remission of chronic fatigue syndrome.2007 · case report · 1 in the study
    Summary

    This case report from Belgium describes one 13-year-old girl with chronic fatigue syndrome (CFS) who was unable to walk or stand and had muscle pain and weakness. She received a combined treatment: antioxidants (L-carnitine, CoQ10, lipoic acid, taurine), a supplement containing L-glutamine, gamma oryzanol and zinc, a specific “leaky gut diet”, and intravenous immunoglobulins (IVIg; sandoglobuline 6 g/day during 1 month, and thereafter 6 g each two weeks for the following months). No comparison group was reported. The paper reports clinical symptoms and serum IgM against the LPS of gram-negative bacteria. During December 2005 to May 2006, no change in the clinical picture could be detected. On August 18, 2006, she regained strength, her concentration was much better and she could read books again, her sleep disorders were much better, and she had restarted swimming classes; she still suffered from non-refreshing sleep and abdominal complaints. On December 8, 2006, her clinical condition was again much better, her sleep became refreshing, and abdominal complaints including bloating were better, although sometimes she had diarrhea and nausea; during one week she had suffered from sore throat and tender lymph nodes. On February 1, 2007, she ascertained that all her symptoms had disappeared. IVIg was stopped, while antioxidants and the leaky gut diet were continued. On July 13, 2007, she finished the school year with a very good score (>80%). By November, 2007, all CFS symptoms were still in remission. No limitations were stated in the supplied text.

  11. Factors involved in the improvement of prolonged symptoms in patients with COVID-19 treated with Japanese traditional (Kampo) medicine: A single-center, prospective, observational study.2026 · combination: given with other treatments · 128 in the study · 114 with outcome data
    Summary

    This single-center, prospective, observational study in Japan enrolled 128 consecutive patients with prolonged symptoms of COVID-19; 114 were analysed. Patients received a symptom-selected regimen that included Kampo formulas (HET, JTT, NYT, BRIHK, yokukansan, TSS, KOSS) and other treatments such as a proton pump inhibitor, acupuncture and moxibustion, zinc preparation, and antihistamines. No control treatment group was included. Outcomes were performance status (PS ≤ 2) and the end-of-visit milestone. In 3 months, 75 (65.8%) patients achieved PS ≤ 2 and 36 (31.6%) achieved the end-of-visit milestone. At 6 months, 60 of 76 patients (78.9%) achieved PS ≤ 2 and 51 of 78 patients (67.9%) achieved the end-of-visit milestone. The group with first-visit general fatigue at or above the median took more time to achieve PS ≤ 2 (hazard ratio 0.405 [0.253–0.650]) and the end-of-visit milestone (0.283 [0.150–0.532]) than the below-median group. The ≥90 days group reached the end-of-visit milestone later (0.510 [0.267–0.974]) than the <90 days group. There were 5 (4.4%) adverse events; 2 patients had liver dysfunction caused by HET or JTT, and both improved after discontinuing the drug.

  12. Case Report: Mitochondrial insufficiency underlies cholinergic failure in post-vaccination long COVID: a candidate treatment protocol.2026 · combination: given with other treatments · 1 in the study
    Summary

    This single self-case report described an 80-year-old male professor with severe post-vaccination long COVID. Mestinon (pyridostigmine bromide) 90 mg daily had provided minimal benefit over 2 months. A comprehensive mitochondrial support protocol was then started: nicotinamide riboside 500 mg daily, ubiquinol one gram daily, high-dose B-complex vitamins, zinc 30 mg daily, copper two mg daily, creatine monohydrate five grams daily, N-acetylcysteine 900 mg daily, vitamin B12 as two chewable tablets daily plus intramuscular injections twice monthly, continued Mestinon 90 mg daily, continued nortriptyline 20 mg daily, all with seven ounces of fresh-squeezed orange juice three times daily. There was no comparison group, blinding or randomization. Clinical response was reported as dramatic within 48 h, with sustained functional recovery over 6 weeks. The report describes symptom recurrence within 4–6 h after missed morning doses on two occasions, resolution within 1–2 h after the delayed dose, minimal benefit with intentional reversal of component sequence for 5 days, complete loss of symptom control and being bedridden when water was substituted for orange juice, and noticeable improvement within 30 min, ability to walk one-eighth mile at 45 min, and complete functional recovery within 1–2 h after the evening dose with orange juice. Validated patient-reported outcome instruments were not administered. The authors state limitations including no blinding or randomization and possible placebo/nocebo effects.

  13. Role of nutrient supplements in children with post-COVID condition: a retrospective preliminary observation and narrative review.2025 · combination: given with other treatments · 1,243 in the study · 1,171 with outcome data
    Summary

    This retrospective preliminary observation and narrative review asked whether nutrient supplements affected long COVID in children. It was a retrospective sub-analysis of a previously published prospective follow-up cohort at a Post-COVID clinic in a third-level hospital in Rome, Italy, from February 2020 to October 2022. During the study period 1243 patients were enrolled; 1171 were in the six-month follow-up table. Children with persistent, disabling symptoms at three months after infection received oral lactoferrin and/or a Multi-Element Product (MEP) as chewable tablets once a day for 90 days. Treatment groups were MEP plus lactoferrin (152 started), lactoferrin alone (18), and MEP alone (9). The outcome was persistence of long COVID at six months following initial infection. As reported, MEP alone (OR 5.7, 95% CI 3.8–8.5) and MEP plus lactoferrin (OR 5.06, 95% CI 3.3–7.6) were associated with a lower risk of long COVID at six months than lactoferrin alone (OR 7.6, 95% CI 5.1–11.4). For therapy started six months or longer after infection, no statistically significant associations were found with Long Covid resolution. Harms were not reported. The authors state the study was retrospective and had no control group, so causality and spontaneous improvement cannot be distinguished.

  14. Ocular and Neurological Sequelae in Long COVID: Dry Eye, Asthenopia, Sleep Disorders, Asthenia, and Restless Legs Syndrome-A Case Report with Literature Review.2025 · combination: given with other treatments · 1 in the study
    Summary

    This case report describes one 59-year-old Caucasian male with long COVID who was evaluated in an ophthalmology clinic for about six weeks of ocular burning, foreign body sensation, and asthenopia, plus asthenia, sleep disturbance, and restless legs syndrome. He received a tear substitute four times a day in both eyes, an antibiotic ointment before bedtime, oral Colinplus Delta®, zinc gluconate 17.4 mg and selenium methionine 100 mcg in the evening, and melatonin 2 mg orally, for six weeks. There was no comparison group; outcomes were compared with before treatment. At 6 weeks the patient reported significant improvement in ocular symptoms and resolution of irritative disorders and asthenopia, with complete resumption of work and daily activities. OSDI was 36 at baseline and 11 at 6 weeks; TBUT was 3 s right and 2 s left at baseline and 9 s right and 8 s left at 6 weeks; Schirmer I was 8 mm right and 6 mm left at baseline and 10 mm right and 9 mm left at 6 weeks. Reading speed improved from 95 to 222 wpm, and PPC from 38 cm to 19 cm. A reduction in asthenia, insomnia, and RLS was reported. Harms and withdrawals were not reported.

  15. Effect of oral zinc and steroids on long COVID hyposmia and hypogeusia.2024 · combination: given with other treatments · 71 in the study
    Summary

    This retrospective study enrolled 71 patients with long COVID and persistent loss of smell and/or taste for >1 month after infection in Taiwan. Thirty-four complained of smell and taste loss, 36 only smell loss, and one only taste loss. Patients received oral prednisolone 10 mg bid and a zinc gluconate tablet 10 mg tid for a month; tests were repeated after 2–4 months of treatment. There was no comparison group. Olfactory and gustatory functions were measured with UPSIT-TC and WETT and assessed by phone at a mean of 10.35 months for the smell-and-taste group and 10.42 months for the smell-only group. Among 18 patients with smell and taste loss who returned, 14/18 (77.8%) remained hyposmic, 11/17 (64.7%) improved, and UPSIT-TC scores increased (p = 0.001). WETT scores increased (p = 0.019); 3/18 (16.7%) remained hypogeusic, and none of the three hypogeusic patients improved. Among 21 smell-only patients who returned, 15/21 (71.4%) remained hyposmic, 11/18 (61.1%) improved, and UPSIT-TC scores increased (p = 0.008). By phone, 31/34 (91.2%) with smell and taste loss reported olfactory improvement and 30/34 (88.2%) gustatory improvement; 77.8% of the 36 smell-only patients reported olfactory improvement. One taste-only patient’s UPSIT-TC score changed from 23 to 19 and WETT score from 1 to 31; she reported partial taste recovery. Side effects were not reported. About half did not return for the second objective test; the authors state no control patients and no sample size calculation.

  16. Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.2021 · combination: given with other treatments · 72 randomised · 60 started · 50 analysed
    Summary

    This 16-week randomized, double-blind, placebo-controlled trial asked whether oral melatonin plus zinc changes fatigue perception in ME/CFS. Participants were women with ME/CFS confirmed by the 1994 CDC/Fukuda case definition, recruited from a single outpatient tertiary referral center in Barcelona. The paper reports 72 randomized, 60 visited at baseline, and 50 completing the final assessment at 20 weeks. The melatonin plus zinc group received 1 mg melatonin plus 10 mg zinc once daily at night for 16 weeks; the comparison group received matching placebo. Outcomes were assessed at baseline, after 8 and 16 weeks of treatment, and 4 weeks post-treatment. Measures included FIS-40 fatigue, SF-36 quality of life, PSQI sleep, HADS anxiety/depression, and urinary 6-sulphatoxymelatonin and serum zinc. The results text reports physical fatigue perception improved at 16 weeks versus placebo (p = 0.026) and versus baseline (p = 0.012) in the melatonin plus zinc group. The SF-36 physical component summary improved at 8 and 16 weeks (p = 0.02 and p = 0.032). The paper reports no between-group differences for FIS-40 total score, SF-36 mental component summary, PSQI components, or HADS domains. It reports worsening after treatment withdrawal in physical functioning (p = 0.011), mental health status (p = 0.003), and sleep latency (p = 0.041). Seven participants (12%) abandoned the study; three (5%) were lost to follow-up. No relevant treatment-related adverse events were recorded. The authors state limitations: a small sample of 50 women, single-center recruitment, pre-established timing and doses, and no control for confounders.

  17. Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome.2014 · combination: given with other treatments · 76 in the study
    Summary

    Seventy-six ME/CFS patients admitted to the Maes Outpatient Clinics, Belgium, were selected for increased (> 2 SD) IgM responses to 3 OSEs or 3 NO-adducts. In this non-interventional study, all patients took a combination of NAIOS—L-carnitine, coenzyme Q10, taurine + lipoic acid, with or without curcumine + quercitine or N-acetyl-cysteine, zinc + glutamine—continued for 14.3 (±4.2) months. There was no separate comparison group; patients also received other care-as-usual treatments. The study measured FF scores and IgM responses to oleic acid, MDA, Pi, NOW, NO-arginine and NO-cysteinyl. Treatment was followed by significant reductions in IgM responses to oleic acid (F=9.03, p=0.004), MDA (F=13.12, p=0.001), Pi (F=20.28, p<0.001), NO-Cysteinyl (F=10.03, p=0.003), NO-Arginine (F=6.99, p=0.011) and NOW (F=6.19, p=0.016). In patients with endpoint FF<12, oleic acid and Pi responses fell more than in those with endpoint FF≥12. Antidepressant use had no significant effect (F=0.17, p=0.843). Harms were not reported. The authors state the non-interventional design could not standardize NAIOS and that supplement quality, content and bioavailability may have biased results.

  18. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria.2008 · combination: given with other treatments · 41 in the study
    Summary

    This non-interventional study asked whether gut-derived LPS translocation and clinical severity change in chronic fatigue syndrome. Forty-one patients were consecutively admitted to the M-Care4U Outpatient Clinics, Belgium, and selected for initial increases in IgM and/or IgA responses to LPS. All followed a leaky gut diet and took glutamine, zinc and NAC, plus other NAIOSs (L-carnitine, coenzyme Q10, taurine, lipoic acid, curcumine, quercitine) for 10-12 months (also reported as 10-14 months). There was no comparison group; before and endpoint measures were compared. Outcomes included the Fibromyalgia and Chronic Fatigue Syndrome Rating Scale (FF scale) and IgM/IgA responses to LPS. The mean FF score was 38.8 at baseline and 14.0 at endpoint. Overall, 26 (63.5%) patients showed a good clinical response, while 15 (36.5%) showed less clinical improvement. At endpoint, responders had FF 7.7 versus non-responders 24.9; patients ill <5 years had 7.3 versus >5 years 18.7; age <38 years had 10.6 versus >38 years 17.6. The overall age comparison was not significant (p=0.2). Side effects and withdrawals were not reported.

  19. Nutraceutical Supplementation Effects on Subjective Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review.2025 · systematic review
    Summary

    Review authors searched ClinicalTrials.gov, Medline, PubMed, Cochrane and Web of Science for interventional studies of nutraceuticals or diet in adults with ME/CFS and included 14 studies, described as randomised controlled trials and open-label pilot trials. Interventions included CoQ10 (alone or with alpha-lipoic acid, NADH or selenium), NADH, melatonin with zinc, anhydrous enol-oxaloacetate, sodium dichloroacetate, hydrogen water, Ginkgo with Cistanche, guanidinoacetic acid, 6-methylsulfinylhexyl isothiocyanate, D-ribose, porcine serum polypeptide and probiotics, given for varying durations, with fatigue measured by self-report scales. CoQ10 plus alpha-lipoic acid lowered FSS scores (p < 0.0001); CoQ10 plus NADH lowered FIS-40 (p = 0.03; p < 0.001) and maximum HR (p = 0.022), with pain and sleep not significant; CoQ10 plus selenium lowered FIS-40 (p = 0.021); melatonin with zinc lowered FIS-40 (p < 0.05) without improving sleep or anxiety; probiotics improved the mental component (p = 0.043). Fatigue was not significant with guanidinoacetic acid, or with 6-MSITC on the CFQ-11. Reported side effects included dyspepsia (2/23 at 500 mg BID and 2/24 at 1,000 mg BID) and insomnia (1/26) with enol-oxaloacetate, epigastralgia and dizziness, tremor in one patient, and symptom flare-up in one patient. A meta-analysis was not conducted.

  20. Preventive interventions for post Covid-19 condition: systematic review update2024 · systematic review · preprint
    Summary

    This systematic review update searched on February 9, 2024 and included 24 studies (5 randomized and 19 non-randomized), all among adults. It examined interventions given during acute or post-acute COVID-19 to prevent post COVID-19 condition (PCC). For convalescent plasma in outpatients (1 trial; N=882), the RR (95% CI) was 0.93 (0.77-1.12), with moderate certainty. For probiotics in outpatients (1 trial; N=69), RR was 0.32 (0.13-0.78), low certainty. For metformin in outpatients (1 trial; N=450), RR was 0.50 (0.25-0.99), low certainty. For ivermectin in outpatients (1 trial; N=374), RR was 0.93 (0.50-1.71), low certainty. Therapeutic-dose heparin versus prophylactic-dose heparin in inpatients (1 trial; N=571) had RR 1.11 (0.94-1.30) for PCC, low certainty; for cognitive impairment RR was 0.49 (0.22 to 1.07), low certainty; and for HRQoL the MD was 0.12 (-3.22 to 3.46) [range 0-100], moderate certainty. In one trial, metformin (n=569) had no serious adverse events per group; fluvoxamine (n=319), ivermectin (n=406), metformin and fluvoxamine (n=336), and metformin and ivermectin (n=401) had no events in any comparison.

  21. Impact of nutrition on long COVID.2026 · review
    Summary

    This narrative review examined nutritional and exercise interventions for long COVID; it did not report its own cohort. It describes a single-site RCT with n = 151 participants; n = 98 received VitK2/D3 and n = 53 received standard of care, and participants who received Vit K2/D3 showed a 7.1% reduction in long COVID symptoms compared to control group. A randomized, double-blind, placebo-controlled trial with n = 80 patients (n = 40 post COVID patients; n = 40 placebo) gave 60 000 IU of Vitamin D weekly for 8 weeks; the vitamin D group showed significant improvements in CFQ, DASS-anxiety and ACE, but no significant changes were found PQSI, DASS depression, TMT, IL-6 or CRP levels; Table 2 entry 11 reported this vitamin D supplementation with very low side effects. A multicentre trial with n = 144 patients (n = 71 vitamin D3 group; n = 71 placebo group) gave a single oral dose of 200 000 IU Vitamin D3 and found no significant differences between Vit D3 and placebo group for listed symptoms and quality of life upto 1 year of follow up. Probiotic mixture VSL#3® reduced fatigue and significantly improved physical functioning and gasterointestinal symptoms. Stopping or worsening was not reported. The review states limitations in trial design.

  22. Exploring the Potential of Dietary Supplements to Alleviate Pain Due to Long COVID.2025 · review
    Summary

    This review explored dietary supplements for pain due to long COVID. It was a review, not a randomised trial; it had no comparison group, and the review itself did not report enrollment, setting, or follow-up. It summarized studies in long COVID or post-COVID syndrome, including studies with 60, 33, 69, 1, 463, 39, 51, 80, 53, 20, and 12 participants. Treatments included acetyl-l-carnitine 500 mg/day, palmitoylethanolamide 600 mg twice daily, PEA-LUT 770 mg, SIM01, VSL#3®, a vitamin D–containing supplement, vitamin D, marine oil enriched in SPMs, a multinutrient supplement, NAC plus guanfacine, and metformin. Durations reported in the recorded findings included 2 weeks, 4 weeks, 6 months, and 10 months. Measured outcomes included pain, persistent post-COVID symptoms, smell recovery, fatigue, memory loss, concentration, gastrointestinal upset, general unwellness, cognitive abilities, physical functioning, anxiety, depression, and long COVID risk. Findings included improvements in pain, fatigue, cognitive symptoms, smell, and some quality-of-life domains; one report noted no improvement in anxiety, depression, performance, or somatization. Recorded side effects were minimal side effects with vitamin D and mild adverse events with LDN; another recorded harms statement concerned antidepressants, and 19 participants discontinued because of adverse events (12 gabapentin, 7 placebo). The authors stated that clinical experience in long COVID-associated pain is still limited.

  23. Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
    Summary

    This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.

  24. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.2025 · review
    Summary

    This narrative review searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to August 2025 and included 211 publications on ME/CFS diagnosis, pathophysiology, assessment, and treatment. It summarized pharmacological and non-pharmacological interventions. Reported examples include a double-blind, randomized, placebo-controlled trial of IVIG in 99 CFS patients that found an absence of dose-dependent efficacy; a Phase III rintatolimod study in 208 ME/CFS patients in which 51.2% of a severely debilitated subgroup (n = 21/41) had a ≥ 25% improvement in exercise treadmill test duration; a 12-week trial in 207 ME/CFS patients reporting significant reductions in fatigue with CoQ10 (200 mg) and nicotinamide adenine dinucleotide (20 mg); LDN showing significant improvement in 73.9% of 218 ME/CFS patients; and a pilot study of 55 ME/CFS patients in which oral minocycline produced favorable symptom improvements for 80% of treatment completers. A pooled analysis of 1,298 ME/CFS patients from eight trials associated CBT with significant reductions in fatigue severity and functional impairment. A pragmatic trial in 241 adolescents (aged 8–17) found no significant inter-group difference between GET and activity management for physical function on the Short-Form 36 at 6 months. A systematic review and meta-analysis reported a significant reduction in fatigue (Hedges’ g = -0.52) and an improvement in physical function with pacing compared with no treatment or routine care. Harms included GET-associated symptom exacerbation in a significant proportion of patients, and rintatolimod adverse events may occur. TCM findings should be cautiously interpreted because the available evidence is constrained by methodological limitations.

  25. A Comprehensive Scoping Review on Diet and Nutrition in Relation to Long COVID-19 Symptoms and Recovery.2025 · review
    Summary

    This scoping review synthesized 50 studies (27 intervention and 23 observational) in adults with long COVID-19, identified through database and manual searches. The review itself had no comparison group and no meta-analysis. Included studies examined vitamin D, multinutrient/nutraceutical formulations, amino acids and metabolic support, creatine, oxaloacetate, nitric-oxide boosters, gut microbiota-targeted therapies, and diet/lifestyle programs; comparisons included placebo, controls, or another formulation. Examples reported: in 80 people with post-COVID-19 syndrome, weekly vitamin D improved fatigue (p = 0.024), anxiety (p = 0.011), and cognitive function (p = 0.012), with no effects on depression, sleep quality, or inflammatory markers. A single 200,000 IU vitamin D3 dose in 144 hospitalized patients showed no benefit on persistent symptoms or quality of life. Magnesium plus vitamin D improved depression (73.2% vs 34.5% remission, p = 0.006). PIRV-F20 in 44 long COVID-19 patients improved six-minute walking distance (+40 m vs +10 m, p = 0.02) but not strength or symptoms. Noni in 188 post-COVID-19 patients reduced fatigue (61.5% vs 24.3%), cognitive symptoms (59.4% vs 21.6%), and joint pain (66.2% vs 33.8%). SIM01 in 463 individuals alleviated core symptoms (all p < 0.01). Beetroot juice in 31 patients showed no significant between-group differences. Side effects and withdrawals were not reported in the recorded data. The authors state no formal quality appraisal was performed and causal inferences cannot be made.

  26. The potential therapeutic approaches targeting gut health in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a narrative review.2025 · review
    Summary

    This narrative review searched English peer-reviewed literature from January 1995 to January 2025 via PubMed, Scopus, and Web of Science to synthesize data on gut microbiota, inflammatory markers, and therapeutic outcomes in ME/CFS. The review did not report enrolling patients. It describes probiotic studies: an Italian pilot 8-week course improved well-being and reduced inflammation; in 15 ME/CFS patients, three strains improved neurocognitive function but no significant fatigue or physical activity reduction in only nine patients; Bifidobacterium infantis 35,624 in 48 patients lowered CRP, TNF-α, and IL-6. A 12-week Ubiquinol-10 randomized trial reported no significant fatigue improvement but reduced night-time awakenings; a 16-week randomized placebo-controlled trial of oral melatonin (1 mg) and zinc (10 mg) in 50 patients showed reductions in physical fatigue and improved quality of life. FMT: a retrospective study of 60 patients reported 70% response after four weeks and 58% maintained resolution for 15–20 years; another reported 17 of 21 patients with at least 60% improvement; a randomized placebo-controlled pilot in 11 patients (5 universal donor, 6 autologous) found no notable quality-of-life differences at 1 and 6 months. A Norway survey reported about 80% declined after graded exercise therapy; structured moderate activity over 12 to 26 weeks reduced fatigue compared with conventional/passive therapies; after a maximal exercise test, pain, fatigue, and confusion changed, with Clostridium in blood at 15 min and Bacilli increased at 48 h. Authors state current research lacks comprehensive insights and studies often produce conflicting findings, with varied diagnostic criteria and small samples.

  27. [Evidence map on post-acute COVID-19 sequelae and rehabilitation: Update as of July 2022Mapa de evidencia sobre las secuelas y la rehabilitación tras la COVID-19 aguda: versión actualizada en julio del 2022].2023 · review
    Summary

    This evidence map updated a review of interventions for rehabilitation of post-acute COVID-19 sequelae in people who had symptomatic COVID-19 and post-acute sequelae; the population was predominantly adults. The update searched Biblioteca Virtual em Saúde and PubMed and was dated 27 July 2022. It included 32 review studies. Interventions were grouped as multimodal, pharmacological, therapeutic, and complementary therapies; no single treatment duration was reported. There was no comparison group; the map plotted associations between interventions and health outcomes. Effects were classified as positive, potentially positive, inconclusive, not informed, or no effect. The map reported 166 associations; the update analysed 69 associations. Exercise (isolated, multicomponent, or multimodal) had 23 positive effects and four potentially positive effects. Exercise prescription was reported with positive effects for functional exercise capacity, lung function, and quality of life; exercise had positive effects for mental health, dyspnoea, fatigue, exercise capacity, and muscle strength, while depression was not informed and lung function was absent and functional independence inconclusive. Pharmacological and complementary interventions for sensory functions had 15 associations. No study reported negative or potentially negative effects. Worsening, discontinuation, and side-effect counts were not reported. The authors state the literature remains incipient and many included items were protocols.

  28. Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities.2019 · review
    Summary

    This review asks why pathophysiological insights in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) might point to treatments, and it examines treatment data for antioxidant and anti-inflammatory options. It reports no primary enrolment or analysis; it discusses patients diagnosed with ME/CFS by international consensus or Fukuda criteria and reviews CBT, GET, curcumin, NAC, CoQ10, melatonin, probiotics/prebiotics and molecular hydrogen. For the PACE trial, it reports that a year of CBT produced modest and short-term reductions in fatigue of some 10% compared with an untreated control group and a non-significant worsening of distance walked in six minutes. It also reports that CBT and GET reduced self-reported fatigue by some 13% compared with no treatment after 52 weeks, that GET improved six-minute walking distance by 31m compared with no treatment, and that GET for 12 months was associated with a 67m improvement versus 22m with specialist medical care alone. In 60 patients selected by international consensus criteria, graded exercise over a 12-month period was reported to worsen physical function and pain. Hydrogen-rich water studies in Parkinson’s disease (1,000 mL/day over a 48-week period) and rheumatoid arthritis (500 mL of 1 ppm for four weeks) reported improvements versus controls. The authors state these data are promising yet preliminary.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime